A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving ...

Intravenous (IV) compounding safety has garnered recent attention as a result of high-profile incidents, awareness efforts from the safety community, and increasingly ...

Merck (MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND® (fosaprepitant dimeglumine) for ...

The approval is primarily based on the phase 3 MK-0517-031 study, in which adding single-dose Emend for injection induced a complete response in nearly 80 percent of patients receiving MEC. The FDA ...